Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (NCT03104491)
🩺 Plain-English Summary (8th-Grade Level)
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
Who can join: Review the eligibility criteria below.
Location: The University of Kansas Cancer Center — Westwood, Kansas
Age range: 16 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- The University of Kansas Cancer Center — Westwood, Kansas
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Nebraska Medical Center — Omaha, Nebraska
- Memorial Sloan Kettering Cancer Center — New York, New York
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (800) 641-2422
Email: CTUReferral@UHhospitals.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Lymphocytic Leukemia
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies — New York, New York
- Pilot Imaging Study of Leukemia — Washington D.C., District of Columbia
Explore by condition: All Acute Lymphocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.